IDXX vs CHWY vs PAHC Stock Comparison

Idexx Laboratories, Chewy and Phibro Animal Health Prices as of Nov 13, 2026 Peers: Industry group
1 more company in this comparison (COR) Create a free account to keep reading and compare up to 10 companies.
CHWY Chewy, Inc.
$22.51 +8.0% 1M -32.8% 1Y
Market cap
$8.79B
P/E
32.1x
Revenue (TTM)
$13.07B
Div. yield
–
Packaged Foods Consumer Staples
1 win

Head to Head

11 decided of 12

Idexx Laboratories leads on 7 of the 12 questions below (Idexx Laboratories 7, Phibro Animal Health 3, Chewy 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIDXXCHWYPAHCLeader
Larger companyMarket capitalisation $55.34B $8.79B $1.42B IDXX
Cheaper on earningsLower P/E, profitable companies only 46.8x 32.1x 13.9x PAHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 44.6x 30.0x 10.6x PAHC
Faster revenue growthRevenue growth, trailing twelve months +11.9% +5.9% +10.1% IDXX
More profitableNet margin, trailing twelve months 25.4% 2.1% 6.7% IDXX
Better return on capitalReturn on invested capital 45.4% — 13.9% IDXX
Less leveragedLower net debt / EBITDA 0.4x 0.0x 2.1x CHWY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +0.4% -32.8% -19.5% IDXX
Better 5-year returnAnnualised price return, 5 years +2.3%/yr -21.8%/yr +9.6%/yr PAHC
Less volatileAnnualised volatility, 1 year 36.2% 47.7% 56.9% IDXX
Higher overall scoreMean of the five percentile scores vs peers 76/100 70/100 72/100 IDXX

Percentile Scorecard

IDXXCHWYPAHC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIDXXCHWYPAHC
Valuation 74 #175 of 660 56 #21 of 46 95 #34 of 660
Growth 70 #184 of 619 90 #5 of 42 93 #46 of 619
Profitability 98 #12 of 595 60 #17 of 41 86 #86 of 595
Financial Health 46 #371 of 683 57 #21 of 48 27 #496 of 683
Shareholder Returns 94 #30 of 459 85 #6 of 34 57 #196 of 459
Overall 76 70 72
  • IDXX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • CHWY ranked among 48 companies in Branded Foods
  • PAHC ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIDXXCHWYPAHCSPY
1 month +33.1%+8.0%-5.2% -2.0%
3 months +27.8%+0.4%+4.7% -2.8%
6 months +33.2%+5.8%+4.7% +2.0%
Year to date +4.1%-31.9%-3.7% +10.6%
1 year +0.4%-32.8%-19.5% +12.2%
3 years +55.0%+11.6%+253.7% +68.1%
3 years, per year +15.7%+3.7%+52.4% +18.9%
5 years +12.1%-70.7%+58.0% +61.4%
5 years, per year +2.3%-21.8%+9.6% +10.1%
10 years +545.1%—+25.3% +248.5%
10 years, per year +20.5%—+2.3% +13.3%

Risk

MeasureIDXXCHWYPAHCSPY
Volatility, 1Y 36.2%47.7%56.9% 13.6%
Downside volatility, 1Y 32.6%48.1%62.8% 13.9%
Beta vs S&P 500, 1Y 0.840.820.97 1.00
Return / volatility, 1Y 0.01-0.69-0.34 0.90
Max drawdown, 5Y -50.9%-80.3%-56.8% -25.4%
From 52-week high -8.1%-36.4%-39.6% -3.2%
52-week high $766.68$35.37$59.58 $779.14
52-week low $504.70$17.51$28.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIDXXCHWYPAHC
P/E now vs peer median 47.0xmedian 17.0x 33.4xmedian 18.9x 14.2xmedian 17.0x
P/S now vs peer median 11.9xmedian 8.4x 0.7xmedian 0.9x 0.9xmedian 8.4x
EV/EBITDA now vs peer median 33.7xmedian 14.6x 19.1xmedian 12.8x 7.8xmedian 14.6x
P/FCF now vs peer median 42.6xmedian 19.0x 15.9xmedian 13.7x 22.2xmedian 19.0x
P/B now vs peer median 29.7xmedian 2.0x 24.4xmedian 1.6x 3.5xmedian 2.0x
PEG now vs peer median 3.10median 0.43 0.44median 0.70 0.14median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIDXXCHWYPAHC
Revenue $4.66B $13.07B $1.54B
Gross profit $2.92B $3.91B $521.27M
Operating income $1.51B $328.20M $192.78M
Net income $1.18B $273.70M $108.21M
Free cash flow $1.30B $568.10M $65.64M
R&D $266.87M – –
EPS (diluted) $14.96 $0.67 $2.51
Cash & equivalents $197.54M $611.00M $75.55M
Total debt $848.88M $591.70M $610.88M
Shares (diluted) 79.05M 410.10M 40.96M
Enterprise value $54.56B $6.08B $1.11B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIDXXCHWYPAHC
P/E 47.0x 33.4x 14.2x
P/FCF 42.6x 15.9x 22.2x
P/Operating cash flow 39.1x 12.6x 15.3x
P/S 11.9x 0.7x 0.9x
P/B 29.7x 24.4x 3.5x
P/Tangible book 31.7x 40.9x 3.7x
EV/EBITDA 33.7x 19.1x 7.8x
EV/EBIT 37.3x 27.5x 10.3x
EV/Revenue 12.0x 0.7x 1.3x
EV/FCF 43.1x 15.9x 30.3x
EV/Operating cash flow 39.6x 12.6x 20.8x
PEG (3Y EPS CAGR) 3.10 0.44 0.14

Growth

14 metrics
MetricIDXXCHWYPAHC
Revenue growth (1Y) 11.9% 5.9% 10.1%
Revenue CAGR (3Y) 9.1% 6.4% 16.4%
Gross profit growth (1Y) 13.7% 7.6% 19.5%
Gross profit CAGR (3Y) 10.8% 8.5% 20.6%
Operating income growth (1Y) 15.3% 102.0% 33.8%
Operating income CAGR (3Y) 11.8% 139.1% 49.7%
Net income growth (1Y) 15.1% 81.1% 47.3%
Net income CAGR (3Y) 12.8% 73.8% 243.2%
EPS growth (1Y) 17.4% 89.2% 51.2%
EPS CAGR (3Y) 15.1% 76.8% 104.0%
Operating cash flow growth (1Y) 30.4% 17.3% 122.6%
Operating cash flow CAGR (3Y) 19.6% 10.9% 24.0%
Free cash flow growth (1Y) 35.3% 22.7% 198.5%
Free cash flow CAGR (3Y) 24.2% 18.6% 30.6%

Profitability

14 metrics
MetricIDXXCHWYPAHC
Gross margin 62.7% 29.9% 33.8%
EBITDA margin 35.7% 3.6% 16.5%
Operating margin 32.3% 2.5% 12.5%
Pretax margin 31.7% 2.7% 9.1%
Net margin 25.4% 2.1% 6.7%
FCF margin 28.0% 4.3% 4.3%
Operating cash flow margin 30.4% 5.5% 6.2%
Return on equity 67.9% 69.0% 25.6%
Return on assets 33.1% 7.8% 6.8%
Return on invested capital 45.4% – 13.9%
Return on capital employed 65.2% 24.9% 15.9%
Asset turnover 1.3x 3.7x 1.0x
Cash conversion (OCF / net income) 1.2x 2.6x 0.9x
Stock comp / revenue 1.4% 2.3% 0.1%

Financial Health

11 metrics
MetricIDXXCHWYPAHC
Debt / assets 22.9% 15.8% 40.3%
Debt / equity 0.5x 1.6x 1.5x
Net debt / EBITDA 0.4x 0.0x 2.1x
Debt / FCF 0.7x 1.0x 9.3x
Liabilities / assets 49.6% 90.1% 72.4%
Equity / assets 50.4% 9.9% 27.6%
Interest coverage 43.5x – 4.2x
Current ratio 1.2x 0.8x 3.2x
Quick ratio 0.7x 0.4x 1.0x
Cash ratio 0.2x 0.3x 0.3x
Altman Z-score 23.56 4.83 3.10

Shareholder Returns

7 metrics
MetricIDXXCHWYPAHC
Dividend yield – – 1.3%
Net buyback yield 1.7% 5.6% –
Shareholder yield 1.7% 5.6% 1.3%
Payout ratio (earnings) – – 18.0%
Payout ratio (FCF) – – 29.7%
Dividend growth (1Y) – – 0.1%
Dividend CAGR (3Y) – – 0.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIDXXCHWYPAHC
Forward P/E 44.6xFY2026 30.0xFY2026 10.6xFY2027
EPS, next fiscal year $15.78FY2026 $0.75FY2026 $3.40FY2027
EPS growth, next FY +20.6%FY2026 +44.2%FY2026 +5.6%FY2027
EPS growth, the year after +12.3% +49.3% +11.2%
Revenue, next fiscal year $5.03BFY2026 $12.87BFY2026 $1.53BFY2027
Revenue growth, next FY +17.0%FY2026 +2.1%FY2026 +0.6%FY2027
Revenue growth, the year after +0.4% +5.5% -0.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIDXXCHWYPAHC
Held by institutions 93.6% 100.0% 51.5%
Institutions holding 1,292 513 210
Change in shares held, QoQ +4.1% -0.4% +3.0%
Institutions buying 590 278 117
Institutions selling 496 156 75
Buyers to sellers 1.19 1.78 1.56

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IDXXCHWYPAHC
IDXX 1.00 0.33 0.29
CHWY 0.33 1.00 0.21
PAHC 0.29 0.21 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, IDXX, CHWY and PAHC?

Idexx Laboratories (IDXX) is the largest by market capitalisation: Idexx Laboratories (IDXX) $55.34B, Chewy (CHWY) $8.79B, Phibro Animal Health (PAHC) $1.42B.

Which stock is cheaper, IDXX, CHWY and PAHC?

Phibro Animal Health (PAHC) trades on the lowest price-to-earnings ratio (Idexx Laboratories (IDXX) 46.8x, Chewy (CHWY) 32.1x, Phibro Animal Health (PAHC) 13.9x). On next year's consensus earnings, Phibro Animal Health (PAHC) is cheapest (Idexx Laboratories (IDXX) 44.6x, Chewy (CHWY) 30.0x, Phibro Animal Health (PAHC) 10.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Idexx Laboratories (IDXX) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +11.9%, Chewy (CHWY) +5.9%, Phibro Animal Health (PAHC) +10.1%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Idexx Laboratories (IDXX) 25.4%, Chewy (CHWY) 2.1%, Phibro Animal Health (PAHC) 6.7%). On return on invested capital, Idexx Laboratories (IDXX) leads (Idexx Laboratories (IDXX) 45.4%, Phibro Animal Health (PAHC) 13.9%).

Which stock has performed better?

Over the past year Idexx Laboratories (IDXX) returned the most: Idexx Laboratories (IDXX) +0.4%, Chewy (CHWY) -32.8%, Phibro Animal Health (PAHC) -19.5%. Over five years, Phibro Animal Health (PAHC) compounded fastest (Idexx Laboratories (IDXX) +2.3%/yr, Chewy (CHWY) -21.8%/yr, Phibro Animal Health (PAHC) +9.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Idexx Laboratories (IDXX) 0.00%, Chewy (CHWY) 0.00%, Phibro Animal Health (PAHC) 0.01%. Idexx Laboratories (IDXX) and Chewy (CHWY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Idexx Laboratories (IDXX) 36.2%, Chewy (CHWY) 47.7%, Phibro Animal Health (PAHC) 56.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IDXX, CHWY and PAHC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.